Baynes Roy D. — SEC Form 4 filings
SEC reporting owner CIK 1680739. 31 Form 4 filings on record with FilingPulse; latest filed 2026-08-21.
Transaction summary — filings shown
Covers all 31 filings on record, filed 2024-01-30 to 2026-08-21. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 22 legs across 9 filings — 137,510 shares, $11,337,453 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 58.
- Largest priced transaction: sale of 16,404 shares @ $145.21 ($2,381,997) in Natera, Inc., filed 2024-11-15.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Natera, Inc. (NTRA) | Director | 15 | — | 14 legs · 50,010 sh · $8,249,253 | 24 |
| Travere Therapeutics, Inc. (TVTX) | Director | 10 | — | 8 legs · 87,500 sh · $3,088,200 | 28 |
| Nurix Therapeutics, Inc. (NRIX) | Director | 3 | — | — | 3 |
| Aardvark Therapeutics, Inc. (AARD) | Director | 2 | — | — | 2 |
| Eikon Therapeutics, Inc. (EIKN) | Chief Medical Officer | 1 | — | — | 1 |
Form 4 filings — Baynes Roy D.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-21 | 4 | Aardvark Therapeutics, Inc. (AARD) | Grant/award (A): 44,964 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Natera, Inc. (NTRA) | Grant/award (A): 1,571 · Grant/award (A): 75 | EDGAR |
| 2026-06-16 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 4,500 @ $21.38 · Sale (S): 4,500 @ $50 · Option exercise (M): 4,500 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 4,000 @ $0 · Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2026-05-15 | 4 | Nurix Therapeutics, Inc. (NRIX) | Grant/award (A): 31,250 (derivative) @ $0 | EDGAR |
| 2026-05-06 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 4,500 @ $18.27 · Sale (S): 4,500 @ $46.65 · Option exercise (M): 4,500 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 9,750 @ $6.82 · Sale (S): 9,750 @ $44.22 · Option exercise (M): 9,750 (derivative) @ $0 | EDGAR |
| 2026-04-28 | 4 | Natera, Inc. (NTRA) | Grant/award (A): 83 | EDGAR |
| 2026-04-16 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 8,000 @ $17.94 · Option exercise (M): 9,000 @ $15.43 · Option exercise (M): 4,500 @ $18.27 · Option exercise (M): 4,500 @ $21.38 · Option exercise (M): 6,750 @ $17.11 · Sale (S): 26,000 @ $41.07 · +6 more | EDGAR |
| 2026-04-07 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 10,000 @ $26.52 · Sale (S): 10,000 @ $33 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2026-03-04 | 4 | Eikon Therapeutics, Inc. (EIKN) | Grant/award (A): 134,088 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Natera, Inc. (NTRA) | Grant/award (A): 70 | EDGAR |
| 2025-11-21 | 4 | Natera, Inc. (NTRA) | Option exercise (M): 5,112 @ $40.93 · Sale (S): 1,250 @ $213.47 · Sale (S): 1,727 @ $214.79 · Sale (S): 2,135 @ $216.07 · Option exercise (M): 600 @ $40.93 · Option exercise (M): 7,068 @ $41.19 · +8 more | EDGAR |
| 2025-11-04 | 4 | Natera, Inc. (NTRA) | Grant/award (A): 93 | EDGAR |
| 2025-07-29 | 4 | Natera, Inc. (NTRA) | Grant/award (A): 108 | EDGAR |
| 2025-07-01 | 4 | Natera, Inc. (NTRA) | Grant/award (A): 2,143 | EDGAR |
| 2025-06-13 | 4 | Aardvark Therapeutics, Inc. (AARD) | Grant/award (A): 30,508 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | Nurix Therapeutics, Inc. (NRIX) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 6,500 @ $0 · Grant/award (A): 19,500 (derivative) @ $0 | EDGAR |
| 2025-04-29 | 4 | Natera, Inc. (NTRA) | Grant/award (A): 116 | EDGAR |
| 2025-03-13 | 4 | Nurix Therapeutics, Inc. (NRIX) | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-02-10 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 10,000 @ $17.44 · Sale (S): 10,000 @ $22 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Natera, Inc. (NTRA) | Grant/award (A): 92 | EDGAR |
| 2025-01-23 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 16,000 @ $17.50 · Sale (S): 16,000 @ $20 · Option exercise (M): 16,000 (derivative) @ $0 | EDGAR |
| 2024-11-15 | 4 | Natera, Inc. (NTRA) | Option exercise (M): 22,000 @ $22.83 · Option exercise (M): 15,230 @ $24.42 · Sale (S): 5,500 @ $144.26 · Sale (S): 16,404 @ $145.21 · Sale (S): 1,770 @ $146.25 · Sale (S): 9,467 @ $147.31 · +4 more | EDGAR |
| 2024-10-29 | 4 | Natera, Inc. (NTRA) | Grant/award (A): 124 | EDGAR |
| 2024-07-30 | 4 | Natera, Inc. (NTRA) | Grant/award (A): 143 | EDGAR |
| 2024-07-02 | 4 | Natera, Inc. (NTRA) | Grant/award (A): 2,964 | EDGAR |
| 2024-05-10 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 6,500 @ $0 · Grant/award (A): 19,500 (derivative) @ $0 | EDGAR |
| 2024-04-30 | 4 | Natera, Inc. (NTRA) | Grant/award (A): 169 | EDGAR |
| 2024-01-30 | 4 | Natera, Inc. (NTRA) | Grant/award (A): 215 @ $63.79 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1680739 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →